Mark Cuban Cost Plus partners with 2nd PBM; hints at insulin market entry

Mark Cuban Cost Plus Drug Co. and pharmacy benefit manager EmsanaRx forged a partnership to launch EmsanaRx Plus Dec. 8. 

EmsanaRx integrates with existing employer-sponsored drug benefits so beneficiaries can find discounts and lower-cost medications without going outside their health insurance. Mr. Cuban's online drug company has nearly 1,000 generic drugs at steep discounts.

EmsanaRx Plus is "a first-of-its-kind supplemental drug discount product designed specifically for employers," the two companies said in a news release. 

"Employers are increasingly recognizing that they're being held hostage by a consolidated industry playing games that cost them more every year without adding value," Greg Baker, CEO of EmsanaRx, said in a statement. "In partnering with Cost Plus Drugs, we will help employers understand where high-cost drugs are a problem in their current benefit design and give them and their employees access to lower-cost alternatives."

This is the second pharmacy benefit manager Cost Plus Drugs has partnered with; in late September, it teamed up with Rightway after deciding to not make its own PBM. 

Other recent moves from Mr. Cuban's drug company includes a potential entrance into the insulin market. On Dec. 7, the company's Twitter account said it was "evaluating a future insulin test program" and seeking consumer feedback. 

"If we offered a 90-day supply of a fast-acting insulin (up to 12 vials/8 packs of pens) for $170 incl. shipping, what would you think?" the account tweeted.

Copyright © 2023 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


Featured Whitepapers

Featured Webinars